关注公众号
收藏产品 产品详情
分子别名（Synonym）
EGFRvIII
表达区间及表达系统（Source）
PE-Labeled Human EGFRvIII, His Tag (EGI-HP2E3) is produced via site-specific conjugation of PE to Human EGFRvIII, His Tag under optimal conditions with a proprietary technology. Human EGFRvIII, His Tag is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Predicted N-terminus: Leu 25
Request for sequence蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 42.2 kDa.
偶联（Conjugate）
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
应用说明（Application）
Please note that this product is NOT compatible to streptavidin detection system.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
推荐产品
数据展示
活性（Bioactivity）-FACS
5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Protocol
用户评价 发表评论
背景介绍
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.
药物研发进展 
联系我们 
项目合作 